300122 · SZSE · China
zhifeishengwu.comFinancials as of FY2025
Makes hepatitis B, HPV, and COVID-19 vaccines in Chongqing and sells them into China's government vaccination program.
What this company is and how it runs — written from structure, not news.
Chongqing Zhifei Biological Products manufactures hepatitis B, HPV, and COVID-19 vaccines at its Chongqing facilities, then moves those doses into China's national immunization program through provincial CDC procurement contracts — the only legal channel through which vaccines can reach the public. Every finished lot must pass batch-release testing run by China's National Medical Products Administration before a single dose can transfer to a CDC, so it is the government's own laboratory calendar, not the speed of the production lines, that controls when doses actually ship. Because provincial CDCs will only issue procurement contracts to suppliers whose lot-tracking and cold-chain documentation already matches their own record-keeping systems, years of executing those contracts have wired Zhifei's production schedule directly into each province's vaccination campaign planning — a coordination layer that a new domestic rival would need a full NMPA requalification cycle plus a separate cycle of CDC contract execution to replicate. The entire structure rests on the manufacturing licences tied to the Chongqing facilities: if the NMPA revoked those licences, every provincial CDC contract would lose its legal basis at once, and the documentation relationships built inside them would become worthless overnight.
How does this company make money?
Most revenue comes from selling doses to provincial CDC offices at prices set through government procurement contracts — one negotiated price per dose, paid by the province. The company also sells directly to private hospitals and clinics. In markets where it holds WHO prequalification, it earns additional revenue from international export sales.
What makes this company hard to replace?
A rival supplier wanting to enter China's CDC procurement system would need to complete a multi-year NMPA requalification process before a single dose could legally be sold. Even after clearing that hurdle, the new supplier would need to build the cold-chain distribution relationships and matching lot-tracking and quality-documentation systems that each provincial health authority requires — all from scratch. There is no shortcut that money alone can buy.
What limits this company?
The company can build more production lines, but it cannot build more NMPA testing capacity — that sits inside government laboratories and cannot be bought or sped up. During busy vaccination seasons, finished doses pile up waiting for regulatory clearance, putting a hard ceiling on how fast doses can actually reach patients no matter how much is manufactured.
What does this company depend on?
The company cannot operate without five things: NMPA manufacturing licences for its Chongqing facilities, lot-release testing capacity at NMPA laboratories, China CDC provincial procurement contracts, adjuvant ingredients sourced from international pharmaceutical suppliers, and cold-chain logistics that keep doses between 2 and 8°C during transport.
Who depends on this company?
Provincial CDC immunization programs rely on the company's supply to run scheduled childhood and adult vaccination campaigns — if supply stopped, those campaigns would face shortages. Private hospitals and clinics in China that stock domestically made HPV and hepatitis B vaccines would have to find expensive imported replacements. China's ability to respond to another COVID-19 outbreak would also shrink, because the company is part of the domestic COVID-19 vaccine production base.
How does this company scale?
Vaccine formulas and quality-control procedures can be copied onto additional production lines inside the existing NMPA-approved Chongqing facilities at relatively low extra cost. What does not scale with money is NMPA lot-release testing — government laboratory capacity is fixed, so every new line the company adds still feeds into the same regulatory bottleneck, and that bottleneck controls how fast doses can ship.
What external forces can significantly affect this company?
China's population is aging, which shifts demand toward adult vaccines and away from childhood doses, forcing the company to adjust what it makes. U.S.-China trade tensions can disrupt the supply and raise the price of imported pharmaceutical ingredients used in production. If the company wants to sell vaccines internationally, it must also meet WHO prequalification standards, which add a separate layer of compliance costs on top of domestic NMPA requirements.
Where is this company structurally vulnerable?
If China's NMPA revoked or refused to renew the manufacturing licences tied to the Chongqing facilities, every provincial CDC procurement contract would lose its legal basis at the same moment. All the documentation history and campaign-coordination relationships built inside those contracts would become useless overnight, because CDCs are only permitted to buy from facilities the NMPA has licensed.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph